Durvalumab with tremelimumab for untreated unresectable hepatocellular carcinoma [ID2725]
In development [GID-TA10571] Expected publication date: 25 August 2021
Search results
503 results
-
-
Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after alectinib or ceritinib [ID2702]
In development [GID-TA10569] Expected publication date: TBC
-
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 3 therapies [ID2701]
In development [GID-TA10568] Expected publication date: TBC
-
Atezolizumab with carboplatin or cisplatin and pemetrexed for untreated advanced non-squamous non-small-cell lung cancer ID1495
In development [GID-TA10395] Expected publication date: TBC
-
Durvalumab with chemotherapy for untreated advanced non-small-cell lung cancer with no EGFR or ALK mutations [ID3751]
In development [GID-TA10616] Expected publication date: TBC
-
Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer [ID3752]
In development [GID-TA10617] Expected publication date: TBC
-
Inebilizumab for treating neuromyelitis optica spectrum disorders [ID1529]
In development [GID-TA10522] Expected publication date: TBC
-
Elotuzumab for multiple myeloma [ID966]
In development [GID-TA10134] Expected publication date: TBC
-
Pembrolizumab for previously treated advanced hepatocellular carcinoma [ID1458]
In development [GID-TA10380] Expected publication date: TBC
-
Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (review of HST3) ID1642
In development [GID-TA10642] Expected publication date: TBC
-
Idasanutlin with cytarabine for treating relapsed or refractory acute myeloid leukaemia [ID1597]
In development [GID-TA10494] Expected publication date: TBC
-
Lenalidomide with R-CHOP for untreated activated diffuse large B-cell lymphoma [ID1611]
In development [GID-TA10480] Expected publication date: TBC
-
Nivolumab for maintenance treatment of extensive stage small-cell lung cancer after chemotherapy ID1264
In development [GID-TA10365] Expected publication date: TBC
-
Nivolumab for small-cell lung cancer after platinum-based chemotherapy [ID1126]
In development [GID-TA10158] Expected publication date: TBC
-
Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (ID1375)
In development [GID-TA10360] Expected publication date: TBC
-
Ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease [ID1514]
In development [GID-TA10429] Expected publication date: TBC
-
Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]
In development [GID-TA10295] Expected publication date: TBC
-
Lumacaftor with ivacaftor for treating cystic fibrosis in children aged 2 to 11 years old homozygous for the F508del mutation [ID1486]
In development [GID-TA10390] Expected publication date: TBC
-
Atezolizumab in combination for untreated squamous non-small-cell lung cancer [ID1481]
In development [GID-TA10546] Expected publication date: TBC
-
Durvalumab for untreated EGFR-negative, ALK-negative non-small-cell lung cancer ID1331
In development [GID-TA10318] Expected publication date: TBC
-
Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]
In development [GID-TA10542] Expected publication date: TBC
-
Nivolumab for untreated advanced hepatocellular carcinoma [ID1248]
In development [GID-TA10221] Expected publication date: TBC
-
Entinostat for treating hormone receptor-positive breast cancer after hormonal therapy ID1260
In development [GID-TA10309] Expected publication date: TBC
-
Ibrutinib for untreated mantle cell lymphoma (ID1221)
In development [GID-TA10185] Expected publication date: TBC
-
KTE-C19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 ID1336
In development [GID-TA10316] Expected publication date: TBC
-
Nitisinone for treating alkaptonuria [ID2691]
In development [GID-TA10659] Expected publication date: TBC
-
Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]
In development [GID-TA10024] Expected publication date: 28 June 2017
-
Waldenstrom's macroglobulinaemia - ibrutinib [ID884]
In development [GID-TA10046] Expected publication date: 22 November 2017
-
Soft tissue or bone sarcoma (metastatic) - ridaforolimus (maintenance) [ID415]
In development [GID-TAG431] Expected publication date: TBC
-
Pancreatic cancer (metastatic) - nimotuzumab (1st line) [ID513]
In development [GID-TAG363] Expected publication date: TBC
-
Lymphoma (follicular non Hodgkin's - advanced) - bortezomib [ID407]
In development [GID-TAG425] Expected publication date: TBC
-
Pulmonary arterial hypertension (adults) - drugs [ID12]
In development [GID-TAG382] Expected publication date: TBC
-
Ovarian (epithelial), fallopian and peritoneal cancer - pazopanib (maintenance) [ID545]
In development [GID-TAG444] Expected publication date: TBC
-
Breast cancer - intensity modulated radiotherapy [ID16]
In development [GID-TAG390] Expected publication date: TBC
-
PEGPH20 with nab-paclitaxel and gemcitabine for treating metastatic pancreatic cancer ID1502
In development [GID-TA10402] Expected publication date: TBC
-
Nintedanib for untreated malignant pleural mesothelioma (ID1424)
In development [GID-TA10359] Expected publication date: TBC
-
Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency ID1498
In development [GID-TA10420] Expected publication date: 23 June 2021
-
Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer ID1169
In development [GID-TA10324] Expected publication date: TBC
-
Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer ID1335
In development [GID-TA10315] Expected publication date: TBC
-
Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after initial platinum-based chemotherapy [ID1518]
In development [GID-TA10504] Expected publication date: TBC
-
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies [ID2697]
In development [GID-TA10582] Expected publication date: 19 May 2021
-
Lenvatinib with everolimus or pembrolizumab for untreated advanced renal cell carcinoma [ID3760]
In development [GID-TA10629] Expected publication date: TBC
-
Breast cancer (HER2 negative, metastatic) - bevacizumab (2nd line) [ID488]
In development [GID-TAG432] Expected publication date: TBC
-
Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]
In development [GID-TAG403] Expected publication date: TBC
-
Obesity - phentermine (with topiramate) [ID543]
In development [GID-TAG439] Expected publication date: TBC
-
Osteoarthritis and rheumatoid arthritis - cox-II inhibitors (review) [ID388]
In development [GID-TAG372] Expected publication date: TBC
-
Chronic iron overload (in people with thalassaemia) - desferrioxamine, deferiprone and deferasirox [ID350]
In development [GID-TAG423] Expected publication date: TBC
-
Prostate cancer - intensity modulated radiotherapy [ID17]
In development [GID-TAG396] Expected publication date: TBC
-
Lung cancer (non-small cell, advanced, inoperable) - liposomal cisplatin (with chemotherapy) [ID657]
In development [GID-TAG496] Expected publication date: TBC
-
Colon cancer (adjuvant) - irinotecan [ID379]
In development [GID-TAG380] Expected publication date: TBC